Heart Biomarker Evaluation in Apnea Treatment
- Conditions
- Cardiovascular DiseaseObstructive Sleep ApneaCoronary Artery Disease
- Interventions
- Other: Healthy Lifestyles and Sleep Education plus PAPOther: Healthy Lifestyles and Sleep Education plus Supplemental OxygenOther: Healthy Lifestyles and Sleep Education
- Registration Number
- NCT01086800
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
This study examines the role of sleep apnea treatment in improving cardiovascular biomarkers.
- Detailed Description
This is a Phase II randomized controlled trial that will evaluate the effects of supplemental nocturnal oxygen or Positive Airway Pressure (PAP) therapy, compared to optimal medical preventive therapy for Cardiovascular Disease (CVD) risk, on biomarkers of CVD risk in Obstructive Sleep Apnea (OSA) patients at high risk for CVD events. The study will focus on patients with moderate to severe OSA but only mild OSA symptoms.
Eligible participants have a history or symptoms of heart disease AND have symptoms of sleep apnea or snoring. Participants will be contributing to medical knowledge about different options that can be used to improve heart disease in people with sleep apnea.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 318
- established Coronary Artery Disease or established cardiovascular disease risk factors
- home sleep test that showed moderately severe sleep apnea
- poorly controlled health
- currently using supplemental oxygen or PAP for OSA
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HLSE plus PAP Healthy Lifestyles and Sleep Education plus PAP - HLSE plus Oxygen Healthy Lifestyles and Sleep Education plus Supplemental Oxygen - Healthy Lifestyles and Sleep Education Healthy Lifestyles and Sleep Education -
- Primary Outcome Measures
Name Time Method To compare the effects of nocturnal supplemental oxygen and PAP versus optimized medical management on biomarkers of cardiovascular risk, including: 3 months * 24 hour blood pressure (BP) profile
* Markers of systemic inflammation
* Markers of oxidative stress
* Prothrombotic markers
* Sympathetic nervous system activity
* Cardiac rhythm, impulse generation and ischemia
* Dyslipidemia
* Glucose regulation
* Myocardial stress
- Secondary Outcome Measures
Name Time Method Compare the effects of nocturnal supplemental oxygen and PAP versus standard care on patient-reported outcomes, including: 3 months * vitality
* self reported sleepinessCompare nocturnal supplemental oxygen and PAP on measures of: 3 months * efficacy (AHI, hypoxemia)
* adherence
* side effects
Trial Locations
- Locations (4)
Case Western Reserve University
๐บ๐ธCleveland, Ohio, United States
Johns Hopkins University
๐บ๐ธBaltimore, Maryland, United States
Partners HealthCare
๐บ๐ธBoston, Massachusetts, United States
VA Boston Healthcare System
๐บ๐ธBoston, Massachusetts, United States